Inhibition of LXR<svg     style="vertical-align:-0.216pt;width:14.1125px;" id="M1" height="10.725" version="1.1" viewBox="0 0 14.1125 10.725" width="14.1125"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.022,-0,0,-.022,.062,10.4)"><path id="x1D736" d="M505 450h125l-163 -259q-1 -4 -1 -12q0 -19 1 -23q9 -98 41 -98q36 0 58 76l24 -7q-34 -139 -121 -139q-32 0 -57.5 24t-31.5 55q-72 -77 -181 -77q-73 0 -114 44t-41 124q0 118 79 210q79 93 197 93q51 0 86 -27t50 -71zM369 281q0 141 -62 141q-43 0 -95 -84
q-52 -82 -52 -195q0 -50 15 -83t42 -33q35 0 79 57q43 58 67 121q6 35 6 76z" /></g>

		
	
</svg>/SREBP-1c-Mediated Hepatic Steatosis by <i  >Jiang-Zhi</i> Granule

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Gene</td><td align="center">Forward primer</td><td align="center">Reverse primer</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Rat LXR<i>α</i></td><td align="center">TCAAGGGAGCACGCTATGTC</td><td align="center">GTTCCTCTTCTTGCCGCTTC</td></tr><tr><td align="left">Rat SREBP-1</td><td align="center">GGTTTTGAACGACATCGAAGA</td><td align="center">CGGGAAGTCACTGTCTTGGT</td></tr><tr><td align="left">Rat FAS</td><td align="center">GGCACTGACTGTCTGTTTTCCA</td><td align="center">GTAAAAATGACACAGTCCAGACACTTC</td></tr><tr><td align="left">Human LXR<i>α</i></td><td align="center">GAGTTTGCCTTGCTCATTGC</td><td align="center">ATCCGTGGGAACATCAGTCG</td></tr><tr><td align="left">Human SREBP-1</td><td align="center">CAGCCCCACTTCATCAAGG</td><td align="center">ACTGTTGCCAAGATGGTTCCG</td></tr><tr><td align="left">Human FAS</td><td align="center">ACTGTTGCCAAGATGGTTCCG</td><td align="center">GGCATCAAACCTAGACAGGTC</td></tr><tr><td align="left">siRNA human LXR<i>α</i></td><td align="center">CGGAACAACTGGGCATGATCGAGAA</td><td align="center">CGGCAACTGGGCATGATCGAAAGAA</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

List of primers used in the present study.

Evidence-Based Complementary and Alternative Medicine

tab1

Table 1

Table 1: Inhibition of LXR<svg     style="vertical-align:-0.216pt;width:14.1125px;" id="M1" height="10.725" version="1.1" viewBox="0 0 14.1125 10.725" width="14.1125"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.022,-0,0,-.022,.062,10.4)"><path id="x1D736" d="M505 450h125l-163 -259q-1 -4 -1 -12q0 -19 1 -23q9 -98 41 -98q36 0 58 76l24 -7q-34 -139 -121 -139q-32 0 -57.5 24t-31.5 55q-72 -77 -181 -77q-73 0 -114 44t-41 124q0 118 79 210q79 93 197 93q51 0 86 -27t50 -71zM369 281q0 141 -62 141q-43 0 -95 -84
q-52 -82 -52 -195q0 -50 15 -83t42 -33q35 0 79 57q43 58 67 121q6 35 6 76z" /></g>

		
	
</svg>/SREBP-1c-Mediated Hepatic Steatosis by <i  >Jiang-Zhi</i> Granule 

Evidence-Based Complementary and Alternative Medicine

Inhibition of LXR /SREBP-1c-Mediated Hepatic Steatosis by Jiang-Zhi Granule

Table 1

Inhibition of LXR/SREBP-1c-Mediated Hepatic Steatosis by Jiang-Zhi Granule